<DOC>
	<DOC>NCT02966548</DOC>
	<brief_summary>This study will be used to determine the safety and tolerability of BMS-986016 administered alone and in combination with Nivolumab in subjects with advanced solid tumors.</brief_summary>
	<brief_title>Safety Study of BMS-986016 With or Without Nivolumab in Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Must have histologic or cytologic confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable) Must have received, and then progressed or been intolerant to, standard treatment regimen in the advanced or metastatic setting, if such a therapy exists Presence of at least one lesion with measurable disease as defined by RECIST v1.1 criteria for response assessment Males and Females, ages 20 years or older, inclusive Known or suspected CNS (central nervous system) metastases or with the CNS as the only site of active disease Other concomitant malignancies (with some exceptions per protocol) Any active autoimmune disease or history of known or suspected autoimmune disease History of uncontrolled or significant cardiovascular disease Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>